Nucleoside analogs: molecular mechanisms signaling cell death

被引:181
作者
Ewald, B. [1 ]
Sampath, D. [1 ]
Plunkett, W. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 71, Houston, TX 77030 USA
关键词
stalled replication forks; DNA damage; DNA repair; sensors; checkpoints; DNA methylation;
D O I
10.1038/onc.2008.316
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nucleoside analogs are structurally similar antimetabolites that have a broad range of action and are clinically active in both solid tumors and hematological malignancies. Many of these agents are incorporated into DNA by polymerases during normal DNA synthesis, an action that blocks further extension of the nascent strand and causes stalling of replication forks. The molecular mechanisms that sense stalled replication forks activate cell cycle checkpoints and DNA repair processes, which may contribute to drug resistance. When replication forks are not stabilized by these molecules or when subsequent DNA repair processes are overwhelmed, apoptosis is initiated either by these same DNA damage sensors or by alternative mechanisms. Recently, strategies aimed at targeting DNA damage checkpoints or DNA repair processes have demonstrated effectiveness in sensitizing cells to nucleoside analogs, thus offering a means to elude drug resistance. In addition to their DNA synthesis-directed actions many nucleoside analogs trigger apoptosis by unique mechanisms, such as causing epigenetic modi. cations or by direct activation of the apoptosome. A review of the cellular and molecular responses to clinically relevant agents provides an understanding of the mechanisms that cause apoptosis and may provide rationale for the development of novel therapeutic strategies.
引用
收藏
页码:6522 / 6537
页数:16
相关论文
共 215 条
[81]  
Johnson S A, 2001, Expert Opin Pharmacother, V2, P929, DOI 10.1517/14656566.2.6.929
[82]   The epigenomics of cancer [J].
Jones, Peter A. ;
Baylin, Stephen B. .
CELL, 2007, 128 (04) :683-692
[83]   Relationships between chromatin organization and DNA methylation in determining gene expression [J].
Jones, PL ;
Wolffe, AP .
SEMINARS IN CANCER BIOLOGY, 1999, 9 (05) :339-347
[84]   Inhibition of the 3'->5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA [J].
Kamiya, K ;
Huang, P ;
Plunkett, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (32) :19428-19435
[85]  
Kanda T, 2005, ONCOL REP, V14, P975
[86]  
KANTARJIAN H, 2007, ASH ANN M, V110, P884
[87]   Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [J].
Kantarjian, Hagop ;
Oki, Yasuhiro ;
Garcia-Manero, Guillermo ;
Huang, Xuelin ;
O'Brien, Susan ;
Cortes, Jorge ;
Faderl, Stefan ;
Bueso-Ramos, Carlos ;
Ravandi, Farhad ;
Estrov, Zeev ;
Ferrajoli, Alessandra ;
Wierda, William ;
Shan, Jianqin ;
Davis, Jan ;
Giles, Francis ;
Saba, Hussain I. ;
Issa, Jean-Pierre J. .
BLOOD, 2007, 109 (01) :52-57
[88]   Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival [J].
Karnitz, LM ;
Flatten, KS ;
Wagner, JM ;
Loegering, D ;
Hackbarth, JS ;
Arlander, SJH ;
Vroman, BT ;
Thomas, MB ;
Baek, YU ;
Hopkins, KM ;
Lieberman, HB ;
Chen, JJ ;
Cliby, WA ;
Kaufmann, SH .
MOLECULAR PHARMACOLOGY, 2005, 68 (06) :1636-1644
[89]  
Kawabe T, 2004, MOL CANCER THER, V3, P513
[90]   Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes [J].
Kicska, GA ;
Long, L ;
Hörig, H ;
Fairchild, C ;
Tyler, PC ;
Furneaux, RH ;
Schramm, VL ;
Kaufman, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (08) :4593-4598